We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Endotis Pharma Forms a Strategic Alliance with Catalent Pharma Solutions
News

Endotis Pharma Forms a Strategic Alliance with Catalent Pharma Solutions

Endotis Pharma Forms a Strategic Alliance with Catalent Pharma Solutions
News

Endotis Pharma Forms a Strategic Alliance with Catalent Pharma Solutions

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Endotis Pharma Forms a Strategic Alliance with Catalent Pharma Solutions"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Endotis Pharma has announced the formation of a strategic alliance with Catalent Pharma Solutions (a worldwide leader in pharmaceutical technologies and services). The two companies will collaborate exclusively to develop certain oral formulations of small-glyco drugs and are now focusing on the preclinical development of Endotis' EP37151 compound.

EP37151 is a first in-class oral synthetic oligosaccharide anticoagulant which, as an indirect factor Xa inhibitor, acts via antithrombin activation. The companies expect to initiate a Phase I clinical trial program during the second quarter of 2010.

Maurice Petitou PhD, Head of Pre-Clinical Research and Development at Endotis Pharma, commented: "Since the initiation of our collaboration with Catalent, we have obtained exciting and self-consistent results on the oral administration of small-glyco drugs. Today, we are delighted to initiate preclinical studies with our first oral anticoagulant. The oral formulation of synthetic oligosaccharides is a major breakthrough that will allow us to fully exploit the therapeutic potential of small-glyco drugs which, to date, have only been administered intravenously or subcutaneously.”
Advertisement